Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Neusoft Xikang Healthcare Technology Co Ltd / Equity Capital Markets

Neusoft Xikang Healthcare Technology Co Ltd (0600187D CH)

Neusoft Xikang Healthcare Technology Co Ltd

Neusoft Xikang, a leading neo-healthcare service provider in China, plans to raise up to USD 400m via a Hong Kong listing.Neusoft Xikang started with providing information integration of healthcare institutions for local governments and expanded its business into online healthcare. It then expanded to provide infrastructure for online and offline healthcare services which became the growth driver in recent years. Analysing the company's competitive position is tricky given the vast scope of its business that deals with government, hospitals, primary healthcare institutions, insurers and patients. So is forecasting the inflection point of its profitability.  Having said that, we think the IPO is still interesting and worth following.

Neusoft Xikang, a leading neo-healthcare service provider in China, plans to raise up to USD 400m via a Hong Kong listing.Neusoft Xikang started with providing information integration of healthcare institutions for local governments and expanded its business into online healthcare. It then expanded to provide infrastructure for online and offline healthcare services which became the growth driver in recent years. Analysing the company's competitive position is tricky given the vast scope of its business that deals with government, hospitals, primary healthcare institutions, insurers and patients. So is forecasting the inflection point of its profitability.  Having said that, we think the IPO is still interesting and worth following.

Ping An Healthcare and Technology (1833 HK)

Neusoft Xikang (东软熙康) Pre-IPO: A Long Way to Profit